Browsing by Author "Akay, MO"
Now showing 1 - 3 of 3
Results Per Page
Sort Options
Item Nodular lymphocyte predominant Hodgkin's lymphoma in daily practice: A multicenter experienceGemici, A; Aydogdu, I; Terzi, H; Sencan, M; Aslan, A; Kaya, AH; Dal, MS; Akay, MO; Dogu, MH; Ayyildiz, O; Sahin, F; Cagliyan, GA; Yilmaz, M; Gokgoz, Z; Bilen, Y; Demir, C; Sevindik, OG; Korkmaz, S; Eser, B; Altuntas, FNodular lymphocyte predominant Hodgkin's lymphoma (NLPHL) is a rare subtype of Hodgkin's lymphoma. In this study, we aimed to investigate the clinical features and therapeutic outcomes of patients with NLPHL who were diagnosed at different institutes in Turkey. We retrospectively reviewed the records of the patients diagnosed with NLPHL. Adult patients who were diagnosed after 2005 with histological confirmation were selected for the study. Forty-three patients were included in the study. Median age of patients was 37.5years (18-70) at the time of diagnosis. About 60.5% patients were diagnosed as stage I and II NLPHL, and remaining 39.5% had stage III and IV disease. Median follow-up was 46months. During follow-up, none of the patients died. Seven patients relapsed or progressed after initial therapy at a median of 12months. Five of 7 relapsed/refractory patients (71.4%) were salvaged with chemotherapy only (DHAP, ICE), and the remaining 2 (28.6%) were salvaged with chemoimmunotherapy. All of relapsed/refractory patients were able to achieve complete remission after salvage therapy. Lactate dehydrogenase levels were significantly higher in patients with progressive disease compared with nonprogressive disease. Our study showed an excellent outcome with all patients alive at last contact with a median follow up of 46months despite a wide range of different therapeutic approaches. All relapsed and refractory patients were successfully salvaged despite a low frequency of patients received immunotherapy in conjunction with chemotherapy. Our results suggest that immunotherapy may be reserved for further relapses.Item Multicenter retrospective analysis regarding the clinical manifestations and treatment results in patients with hairy cell leukemia: twenty-four year Turkish experience in cladribine therapyHacioglu, S; Bilen, Y; Eser, A; Sivgin, S; Gurkan, E; Yildirim, R; Aydogdu, I; Dogu, MH; Yilmaz, M; Kayikci, O; Tombak, A; Kuku, I; Celebi, H; Akay, MO; Esen, R; Korkmaz, S; Keskin, AIn this multicenter retrospective analysis, we aimed to present clinical, laboratory and treatment results of 94 patients with Hairy cell leukemia diagnosed in 13 centers between 1990 and 2014. Sixty-six of the patients were males and 28 were females, with a median age of 55. Splenomegaly was present in 93.5% of cases at diagnosis. The laboratory findings that came into prominence were pancytopenia with grade 3 bone marrow fibrosis. Most of the patients with an indication for treatment were treated with cladribine as first-line treatment. Total and complete response of cladribine was 97.3% and 80.7%. The relapse rate after cladribine was 16.6%, and treatment related mortality was 2.5%. Most preferred therapy ( 95%) was again cladribine at second-line, and third line with CR rate of 68.4% and 66.6%, respectively. The 28-month median OS was 91.7% in all patients and 25-month median OS 96% for patients who were given cladribine as first-line therapy. In conclusion, the first multicenter retrospective Turkish study where patients with HCL were followed up for a long period has revealed demographic characteristics of patients with HCL, and confirmed that cladribine treatment might be safe and effective in a relatively large series of the Turkish study population. Copyright (C) 2014 John Wiley & Sons, Ltd.Item HAIRY CELL LEUKEMIA: MULTICENTER RETROSPECTIVE ANALYSIS IN TURKEYHacioglu, S; Bilen, Y; Eser, A; Sivgin, S; Gurkan, E; Yildirim, R; Aydogdu, I; Dogu, MH; Yilmaz, M; Kayikci, O; Tombak, A; Kuku, I; Celebi, H; Akay, MO; Esen, R; Korkmaz, S; Keskin, A